An important critique to the limited efficacy of anti-PD-1 monotherapy in paediatric sarcoma patients is that many trials, particularly the earlier ones, did not include a priori testing for a predictive biomarker of response, such as immunohistochemical assessment of PD-1/PD-L1 tumour expression, to select patients most likely to respond. This evidence concerns the gene CD274 and sarcoma.